Proov (MFB Fertility, Inc.) develops at-home hormone tests and created the first and only FDA-cleared PdG-testing kit to confirm ovulation quality. Its patented PdG protocol and the Proov Insight app provide quantitative hormone results, end-of-cycle reports, and stored hormone trends without an external reader. The company expanded its product lineup to include Proov Predict & Confirm and has launched Proov Complete, an at-home suite that measures FSH, LH, E1G (estrogen marker) and PdG. Proov says the Complete product and app deliver a comprehensive and affordable at-home hormonal pattern analysis across the menstrual cycle. The company was originally co-founded in Boulder, Colo. by two women who struggled to conceive and is led by CEO Amy Beckley. Proov raised a Series A to support the Complete product and to expand accessibility and physician partnerships. Proov is an at-home fertility diagnostics company launched by MFB Fertility Inc. in 2018 and co-founded in Boulder, Colorado by two women who struggled to conceive. Its FDA-approved test measures the progesterone metabolite PdG in urine to help women confirm ovulation; low progesterone is cited as a leading cause of infertility and preventable miscarriage. Demand for at-home testing kits has surged amid Covid-19, driving the company to scale production and accelerate research and development. The company recently received undisclosed funding from Lightship Capital and the Texas HALO Fund, plus additional angel investors, to support growth and new product launches. Proov also holds a $1.3 million contract with the U.S. Air Force to provide free kits and connect military couples with fertility specialists. CEO Amy Beckley said the investment will help Proov expand its product offering and continue developing fertility tools to deliver more accessible reproductive-health solutions.

Total raised

$10M

Funding rounds

2

Latest round

Series A

Latest activity

Sep 2022